Proton beam therapy reduces the incidence of acute haematological and gastrointestinal toxicities associated with craniospinal irradiation in pediatric brain tumors

References

• Yoon M, Shin DH, Kim J, Kim JW, Kim DW, Park SY, et al. Craniospinal irradiation techniques: A dosimetric comparison of proton beams with standard and advanced photon radiotherapy. Int J Radiat Oncol Biol Phys 2011; 81:637–46.
   PubMed Web of Science ®Google Scholar
• Miralbell R, Lomax A, Cella L, Schneider U. Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors. Int J Radiat Oncol Biol Phys 2002;54:824–9.
   PubMed Web of Science ®Google Scholar
• Timmermann B, Lomax AJ, Nobile L, Grotzer MA, Weiss M, Kortmann RD, et al. Novel technique of craniospinal axis proton therapy with the spot-scanning system: Avoidance of patching multiple fields and optimized ventral dose distribution. Strahlenther Onkol 2007;183:685–8.
   PubMed Web of Science ®Google Scholar
• Kaushansky K. Determinants of platelet number and regulation of thrombopoiesis. Hematology Am Soc Hematol Educ Program 2009:147–52.
   PubMedGoogle Scholar
• Martin TG, 3rd, Somberg KA, Meng YG, Cohen RL, Heid CA, de Sauvage FJ, et al. Thrombopoietin levels in patients with cirrhosis before and after orthotopic liver transplantation. Ann Intern Med 1997;127:285–8.
   PubMed Web of Science ®Google Scholar
• Qian S, Fu F, Li W, Chen Q, de Sauvage FJ. Primary role of the liver in thrombopoietin production shown by tissue-specific knockout. Blood 1998;92:2189–91.
   PubMed Web of Science ®Google Scholar
• Sungaran R, Markovic B, Chong BH. Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood 1997;89:101–7.
   PubMed Web of Science ®Google Scholar
• Yuh GE, Loredo LN, Yonemoto LT, Bush DA, Shahnazi K, Preston W, et al. Reducing toxicity from craniospinal irradiation: Using proton beams to treat medulloblastoma in young children. Cancer J 2004;10:386–90.
   PubMed Web of Science ®Google Scholar
• Brodin NP, Munck Af Rosenschold P, Aznar MC, Kiil-Berthelsen A, Vogelius IR, Nilsson P, et al. Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. Acta Oncol 2011;50:806–16.
   PubMed Web of Science ®Google Scholar
• Zhang R, Howell RM, Giebeler A, Taddei PJ, Mahajan A, Newhauser WD. Comparison of risk of radiogenic second cancer following photon and proton craniospinal irradiation for a pediatric medulloblastoma patient. Phys Med Biol 2013;58:807–23.
   PubMed Web of Science ®Google Scholar
• Brodin NP, Vogelius IR, Maraldo MV, Munck af Rosenschold P, Aznar MC, Kiil-Berthelsen A, et al. Life years lost – comparing potentially fatal late complications after radiotherapy for pediatric medulloblastoma on a common scale. Cancer 2012;118:5432–40.
   PubMed Web of Science ®Google Scholar
• Howell RM, Giebeler A, Koontz-Raisig W, Mahajan A, Etzel CJ, D’Amelio AM, Jr., et al. Comparison of therapeutic dosimetric data from passively scattered proton and photon craniospinal irradiations for medulloblastoma. Radiat Oncol 2012;7:116.
   PubMed Web of Science ®Google Scholar
• Zhang R, Howell RM, Homann K, Giebeler A, Taddei PJ, Mahajan A, et al. Predicted risks of radiogenic cardiac toxicity in two pediatric patients undergoing photon or proton radiotherapy. Radiat Oncol 2013;8:184.
   PubMed Web of Science ®Google Scholar
• Lundkvist J, Ekman M, Ericsson SR, Jonsson B, Glimelius B. Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma. Cancer 2005;103:793–801.
   PubMed Web of Science ®Google Scholar
• Johnstone PA, McMullen KP, Buchsbaum JC, Douglas JG, Helft P. Pediatric CSI: Are protons the only ethical approach? Int J Radiat Oncol Biol Phys 2013;87:228–30.
   PubMed Web of Science ®Google Scholar
• Brown AP, Barney CL, Grosshans DR, McAleer MF, de Groot JF, Puduvalli VK, et al. Proton beam craniospinal irradiation reduces acute toxicity for adults with medulloblastoma. Int J Radiat Oncol Biol Phys 2013;86:277–84.
   PubMed Web of Science ®Google Scholar
• Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. New Engl J Med 2012; 367:11–9.
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Takeshita A, Souda K, Kobayashi Y, Kikuyama M, Suzuki F, et al. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 1999;94:1918–22.
   PubMed Web of Science ®Google Scholar
• Koruk M, Onuk MD, Akcay F, Savas MC. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis, and its relationship with circulating thrombocyte counts. Hepatogastroenterology 2002;49:1645–8.
   PubMed Web of Science ®Google Scholar
• Shimodaira S, Ishida F, Ichikawa N, Tahara T, Kato T, Kodaira H, et al. Serum thrombopoietin (c-Mpl ligand) levels in patients with liver cirrhosis. Thromb Haemost 1996;76:545–8.
   PubMed Web of Science ®Google Scholar
• Vyzantiadis T, Theodoridou S, Giouleme O, Evgenidis N, Vyzantiadis A, Garipidou V. Serum thrombopoietin levels in thrombocytopenic patients with liver cirrhosis. Haematologica 2002;87:890–1.
   PubMed Web of Science ®Google Scholar